Skip to main content
Clinical Trials/ISRCTN21727048
ISRCTN21727048
Completed
Phase 1

A Phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults

niversity of Birmingham0 sites49 target enrollmentMarch 27, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Birmingham
Enrollment
49
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38357205/ (added 15/02/2024)

Registry
who.int
Start Date
March 27, 2018
End Date
October 16, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 1\- \<25 years old at the time of study registration
  • 2\. Histologically confirmed disease in one of the following four groups:
  • 2\.1\. Group 1 \- Acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML)
  • 2\.2\. Group 2 \- Neuroblastoma
  • 2\.3\. Group 3 \- Sarcoma
  • 2\.4\. Group 4 \- High grade glioma (as defined by 2016 WHO CNS classification)
  • 3\. Radiological or laboratory evidence of disease progression (during or after completion of first line treatment) or any subsequent recurrence (biopsy at relapse is not mandated)
  • 4\. Measurable bone marrow disease (group 1\) or at least one evaluable radiological site of disease (group 2, 3 and 4\)
  • 5\. Adequate liver function defined as a total bilirubin \=1\.5x the upper limit of normal for age and ALT \= 3x the upper limit of normal for age
  • 6\. Documented negative pregnancy test for female patients of childbearing potential within 7 days of trial entry

Exclusion Criteria

  • 1\. Previous treatment with another therapeutic arginine\-depleting drug (bacterial or human) or arginase inhibitor
  • 2\. Presence of any \>\= CTCAE grade 3 clinically significant treatment\-related toxicity from prior therapies
  • 3\. Pregnant or lactating female
  • 4\. Evidence of uncontrolled infection

Outcomes

Primary Outcomes

Not specified

Similar Trials